Optimal practices for the management of hereditary transthyretin amyloidosis: real-world experience from Japan, Brazil, and Portugal

被引:5
|
作者
Ando, Yukio [1 ]
Waddington-Cruz, Marcia [2 ]
Sekijima, Yoshiki [3 ]
Koike, Haruki [4 ,5 ]
Ueda, Mitsuharu [6 ]
Konishi, Hiroaki [7 ]
Ishii, Tomonori [7 ]
Coelho, Teresa [8 ]
机构
[1] Nagasaki Int Univ, Fac Pharmaceut Sci, Dept Amyloidosis Res, 2825-7 Huis Ten Bosch Sasebo, Sasebo, Nagasaki 8593298, Japan
[2] Univ Fed Rio de Janeiro, Hosp Univ Clementino Fraga Filho, Ctr Estudos Paramiloidose Antonio Rodrigues Mello, Rio De Janeiro, RJ, Brazil
[3] Shinshu Univ, Sch Med, Dept Med Neurol & Rheumatol, Matsumoto, Japan
[4] Nagoya Univ, Dept Neurol, Grad Sch Med, Nagoya, Japan
[5] Saga Univ, Fac Med, Dept Internal Med, Div Neurol, Saga, Japan
[6] Kumamoto Univ, Grad Sch Med Sci, Dept Neurol, Kumamoto, Japan
[7] Pfizer Japan Inc, Tokyo, Japan
[8] Ctr Hosp Univ Porto, Hosp Santo Antonio, Andrades Ctr Familial Amyloidosis, Porto, Portugal
关键词
Asymptomatic; ATTR amyloidosis; Biopsy; Cardiomyopathy; Gene mutation carrier; Genetic counseling; Neuropathy; Noninvasive testing; Practical guidance; Predictive genetic testing; CARPAL-TUNNEL-SYNDROME; DIAGNOSTIC-ACCURACY; POLYNEUROPATHY; SYMPTOM; ONSET; PROGRESSION; PREVALENCE; TAFAMIDIS; CONSENSUS; FOCUS;
D O I
10.1186/s13023-023-02910-3
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Hereditary transthyretin (ATTRv) amyloidosis is a rare and autosomal dominant disorder associated with mutations in the transthyretin gene. Patients present with diverse symptoms related to sensory, motor, and autonomic neuropathy, as well as gastrointestinal, ocular, cardiac, renal and orthopedic symptoms, resulting from the deposition of transthyretin amyloid fibrils in multiple organs. The progressive nature of ATTRv amyloidosis necessitates pre- and post-onset monitoring of the disease. This review article is primarily based on a collation of discussions from a medical advisory board meeting in August 2021. In this article, we summarize the best practices in amyloidosis centers in three major endemic countries for ATTRv amyloidosis (Japan, Brazil, and Portugal), where most patients carry the Val30Met mutation in the transthyretin gene and the patients' genetic background was proven to be the same. The discussions highlighted the similarities and differences in the management of asymptomatic gene mutation carriers among the three countries in terms of the use of noninvasive tests and tissue biopsies and timing of starting the investigations. In addition, this article discusses a set of practical tests and examinations for monitoring disease progression applicable to neurologists working in diverse medical settings and generalizable in non-endemic countries and areas. This set of assessments consists of periodic (every 6 to 12 months) evaluations of patients' nutritional status and autonomic, renal, cardiac, ophthalmologic, and neurological functions. Physical examinations and patient-reported outcome assessments should be also scheduled every 6 to 12 months. Programs for monitoring gene mutation carriers and robust referral networks can aid in appropriate patient management in pre- to post-onset stages. For pre- and post-symptom onset testing for ATTRv amyloidosis, various noninvasive techniques are available; however, their applicability differs depending on the medical setting in each country and region, and the optimal option should be selected in view of the clinical settings, medical environment, and available healthcare resources in each region.
引用
收藏
页数:17
相关论文
共 50 条
  • [11] Real-World Efficacy of Tafamidis in Patients With Transthyretin Amyloidosis and Heart Failure
    Ghoneem, Ahmed
    Bhatti, Ammar W.
    Khadke, Sumanth
    Mitchell, Joshua
    Liu, Jennifer
    Zhang, Kathleen
    Trachtenberg, Barry
    Wechalekar, Ashutosh
    Cheng, Richard K.
    Baron, Suzanne J.
    Nohria, Anju
    Lenihan, Daniel
    Ganatra, Sarju
    Dani, Sourbha S.
    CURRENT PROBLEMS IN CARDIOLOGY, 2023, 48 (06)
  • [12] Real-World Efficacy of Tafamidis in Patients With Transthyretin Amyloidosis and Heart Failure
    Ghoneem, Ahmed
    Bhatti, Ammar W.
    Mitchell, Joshua D.
    Liu, Jennifer
    Zhang, Kathleen
    Trachtenberg, Barry
    Wechalekar, Ashtoush
    Cheng, Richard
    Baron, Suzanne J.
    Nohria, Anju
    Lenihan, Daniel
    Dani, Sourbha
    Ganatra, Sarju
    CIRCULATION, 2022, 146
  • [13] Real-world outcomes in non-endemic hereditary transthyretin amyloidosis with polyneuropathy: a 20-year German single-referral centre experience
    Ungerer, Matthias N.
    Hund, Ernst
    Purrucker, Jan C.
    Huber, Laura
    Kimmich, Christoph
    Siepen, Fabian aus dem
    Hein, Selina
    Kristen, Arnt, V
    Hinderhofer, Katrin
    Kollmer, Jennifer
    Schoenland, Stefan
    Hegenbart, Ute
    Weiler, Markus
    AMYLOID-JOURNAL OF PROTEIN FOLDING DISORDERS, 2021, 28 (02): : 91 - 99
  • [14] Italian Real-Life Experience of Patients with Hereditary Transthyretin Amyloidosis Treated with Patisiran
    Di Stefano, Vincenzo
    Fava, Antonella
    Gentile, Luca
    Guaraldi, Pietro
    Leonardi, Luca
    Poli, Loris
    Tagliapietra, Matteo
    Vastola, Michele
    Fanara, Salvatore
    Ferrero, Bruno
    Giorgi, Mauro
    Perfetto, Federico
    Russo, Massimo
    Russo, Domitilla
    PHARMACOGENOMICS & PERSONALIZED MEDICINE, 2022, 15 : 499 - 514
  • [15] Response to therapy with tafamidis 61 mg in patients with cardiac transthyretin amyloidosis: real-world experience since approval
    Siepen, Fabian Aus Dem
    Meissner, Christopher
    Hofmann, Eva
    Hein, Selina
    Nagel, Christian
    Hegenbart, Ute
    Schoenland, Stefan O.
    Andre, Florian
    Frey, Norbert
    Kristen, Arnt V.
    AMYLOID-JOURNAL OF PROTEIN FOLDING DISORDERS, 2024, 31 (03): : 226 - 231
  • [16] Utility of Kumamoto Criteria in Diagnosing Transthyretin Cardiac Amyloidosis in Real-World Practice
    Kubota, Toru
    Sunagawa, Genya
    Nagatomo, Daisuke
    Tsutsui, Yoshitomo
    Tsutsui, Hiroyuki
    CIRCULATION JOURNAL, 2020, 84 (04) : 680 - 680
  • [17] Real-world characteristics and treatment of cardiac transthyretin amyloidosis: A multicentre, observational study
    Nies, Richard J.
    Ney, Svenja
    Kindermann, Ingrid
    Bewarder, Yvonne
    Zimmer, Angela
    Knebel, Fabian
    Hahn, Katrin
    Spethmann, Sebastian
    Luedike, Peter
    Michel, Lars
    Rassaf, Tienush
    Papathanasiou, Maria
    Stoerk, Stefan
    Cejka, Vladimir
    Polzin, Amin
    Voss, Fabian
    Kelm, Malte
    Unsoeld, Bernhard
    Meindl, Christine
    Paulus, Michael
    Yilmaz, Ali
    Chamling, Bishwas
    Morbach, Caroline
    Pfister, Roman
    ESC HEART FAILURE, 2025, 12 (02): : 1203 - 1216
  • [18] A retrospective survey of patients with hereditary transthyretin-mediated (hATTR) amyloidosis treated with patisiran in real-world clinical practice in Belgium
    De Bleecker, Jan L.
    Claeys, Kristl G.
    Delstanche, Stephanie
    Van Parys, Vinciane
    Baets, Jonathan
    Tilleux, Sebastien
    Remiche, Gauthier
    ACTA NEUROLOGICA BELGICA, 2023, 123 (03) : 1029 - 1037
  • [19] A retrospective survey of patients with hereditary transthyretin-mediated (hATTR) amyloidosis treated with patisiran in real-world clinical practice in Belgium
    Jan L. De Bleecker
    Kristl G. Claeys
    Stéphanie Delstanche
    Vinciane Van Parys
    Jonathan Baets
    Sébastien Tilleux
    Gauthier Remiche
    Acta Neurologica Belgica, 2023, 123 : 1029 - 1037
  • [20] Hereditary spastic paraparesis: The real-world experience from a Neurogenetics outpatient clinic
    Cunha, Ines A.
    Ribeiro, Joana A.
    Santos, Maria Cj
    EUROPEAN JOURNAL OF MEDICAL GENETICS, 2022, 65 (03)